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Background: Previous studies suggested a relationship between aspirin use and mortality reduction. The mechanism for the
effect of aspirin on cancer outcomes remains unclear. The aim of this study was to evaluate aspirin use and survival in patients with
gastrointestinal tract cancer.
Methods: Patients with gastrointestinal tract cancer diagnosed between 1998 and 2011 were included. The population-based
Eindhoven Cancer Registry was linked to drug-dispensing data from the PHARMO Database Network. The association between
aspirin use after diagnosis and overall survival was analysed using Cox regression models.
Results: In total, 13 715 patients were diagnosed with gastrointestinal cancer. A total of 1008 patients were identified as aspirin
users, and 8278 patients were identified as nonusers. The adjusted hazard ratio for aspirin users vs nonusers was 0.52 (95% CI 0.44–
0.63). A significant association between aspirin use and survival was observed for patients with oesophageal, hepatobiliary and
colorectal cancer.
Conclusions: Post-diagnosis use of aspirin in patients with gastrointestinal tract malignancies is associated with increased survival
in cancers with different sites of origin and biology. This adds weight to the hypothesis that the anti-cancer effects of aspirin are
not tumour-site specific and may be modulated through the tumour micro-environment.
The incidence of cancer is increasing, particularly in low-and
medium-resource countries; by the end of 2015 there were an
estimated 15.2 million new cases globally with a predicted increase
to 21.6 million by 2030 (Sullivan et al, 2015). The cost of health
care is also increasing, and there is a real need for reasonably
priced, widely available therapeutics to improve cancer outcomes.
Although, the US Food and Drug Administration has approved a
higher percentage of oncology drugs since 2008, many of these are
expensive targeted agents with approvals based on surrogate end
points, and infrequently improve overall survival (Kim and Prasad,
2015). Aspirin (acetylsalicylic acid) was originally synthesised and
used as an analgesic in 1897, with the anti-platelet functions of
low-dose aspirin subsequently discovered in the early 1970s. This
latter discovery led to many large randomised controlled trials
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delineating the role of aspirin in the treatment and prevention of
vascular disease. Retrospective long-term analyses of cancer
outcomes in these randomised trials have revealed two interesting
phenomena. Firstly, there was a 24% reduction in cancer incidence
in patients allocated to aspirin, and this effect was seen across
tumour types but was most marked in tumours arising from the
gastrointestinal tract. Secondly, if cancers did develop they were
less likely to have metastasised at presentation or subsequently if
the patient received aspirin (Rothwell et al, 2011, 2012; Algra and
Rothwell, 2012; Cook et al, 2013).
Much of the work to date relating to aspirin and cancer has
focussed on colorectal cancer. In particular there have been several
epidemiological studies showing a reduction in cancer mortality
and improved overall survival for patients taking aspirin after a
diagnosis of colorectal cancer (Chia et al, 2012; Jacobs et al, 2012;
Paleari et al, 2015; Coyle et al, 2016; Elwood et al, 2016). This has
led to several ongoing adjuvant studies in colorectal cancer; the
Add-Aspirin trial (Langley and Rothwell, 2014), Adjuvant Aspirin
for Colon Cancer (NCT02467582), the ALASCCA trial
(NCT02647099), the ASCOLT trial (NCT00565708) and the
Aspirin trial (NCT02301286). In addition, two other randomised
controlled trials have focussed on primary prevention, and after
long-term follow-up showed a beneficial effect on primary
prevention in both hereditary and sporadic colorectal cancer
(Burn et al, 2011; Cook et al, 2013). Also, a meta-analysis of four
other randomised controlled trials showed an absolute risk
reduction of 6.7% for the recurrence of adenoma’s in patients
with a history of these lesions (Cole et al, 2009).
The mechanism(s) underlying the beneficial effects of aspirin on
cancer outcomes remains unclear. Several different potential
biomarkers have been investigated, but due to the multiple
potential cellular pathways and conflicting results of previous
studies, the mechanism of action remains unknown; although
platelets may have a central role (Langley et al, 2011). The aim of
this study was to provide epidemiological evidence and further
mechanistic insights on the potential beneficial effects of aspirin
use after diagnosis of cancer that arises from any part of the
gastrointestinal tract. Because many studies have tried to
differentiate effects of aspirin use both before and after diagnosis,
an additional analysis was performed including the patients that
use aspirin both pre- and post diagnosis.
MATERIALS AND METHODS
Study population. Data from the Eindhoven Cancer Registry was
used to identify patients diagnosed with cancer of the gastro-
intestinal tract between January 1998 and December 2011 in the
south of the Netherlands. This area is served by 10 hospitals, covers
a demographic region of approximately 1.5 million Dutch citizens
and is part of the nationwide Netherlands Comprehensive Cancer
Organisation. The Eindhoven Cancer Registry is linked to the
municipal population registry, which records the vital status (alive/
dead) of all inhabitants. Patients are informed about the
registration and registered except patients who objected to be
registered. The Netherlands Cancer Registry is obliged to work
according to the law about protection of privacy data; informed
consent of the patients for this specific study was not applicable.
Patient selection and data cleaning was performed by the
Eindhoven Cancer Registry. Follow-up for this project was until
31 December 2012.
The PHARMO Database Network is a population-based
network which combines data from different health-care settings
in the Netherlands. For this study the out-patient pharmacy
database was used, which contains drug-dispensing records from
all community pharmacies. Drugs are coded using the Anatomical
Therapeutic Chemical classification (www.whocc.no/atc_ddd_
index) and the records include information on the type of product,
date prescribed, dose and regimen, quantity and route of
administration. The PHARMO database was linked to the
Eindhoven Cancer Registry and thus allows drug use by cancer
patients to be analysed (van Herk-Sukel et al, 2010). From this
linked database, prescriptions for aspirin (only the ones that were
actually dispensed) were selected.
Definition of users and nonusers. For this study, patients
older than 18 years who used aspirin after a diagnosis of a
gastrointestinal cancer were selected. The gastrointestinal tumours
were coded according to the International Classification of Disease
10 [ICD-10] C15-C26. This comprises cancer from the following
sites: oesophagus; stomach; small intestine; colon; recto-sigmoid
and rectum; anus; liver and intra hepatic bile ducts; gallbladder and
extra hepatic bile ducts; pancreas; and a group ‘gastrointestinal
tumours not otherwise specified (nos)’.
Patients who used aspirin before diagnosis were excluded from
the analyses. Aspirin users (ATC codes: B01AC06, B01AC08,
B01AC56, N02BA01, N02BA15, N02BA51, N02BA65) were
defined as those prescribed aspirin for at least 30 days. Nonusers
were defined as patients who received for less than 30 days or never
used aspirin. Time after diagnoses was defined in periods of use
and no use by analysing each single prescription during follow-up.
Periods of less than 14 days in between two prescriptions were
considered consecutive. Follow-up started 14 days after diagnosis
because there was no information about in-hospital use of
medication. Immortal time bias is avoided by analysing prescrip-
tions as a time-varying covariate, in periods of use and no use
(Stricker and Stijnen, 2010; Suissa and Azoulay, 2012).
Statistical analysis. Information from the ECR-contained infor-
mation about the presence or absence of the following comorbid-
ities at cancer diagnosis: lung disease; cardiovascular disease;
diabetes and disorders of the gastrointestinal tract; urinary tract;
nervous system; musculoskeletal system; and a group of other
comorbidities. Comorbidity was analysed as 0, 1 or X2
comorbidities. A w2-test was used to assess baseline characteristics
for categorical values.
Survival analysis were performed with the Simon–Makuch
method, an alternative for Kaplan–Meier and with the ability to
process time-varying covariates in survival curves (Simon and
Makuch, 1984). A Cox proportional hazards model was used with
aspirin use as a time-varying covariate, as described by Stricker and
Stijnen (2010). Schoenfeld residuals were tested to verify the
assumption of proportional hazards. Follow-up duration (survival)
was recorded in months from diagnosis (t¼ 0). Multivariable
survival models were built with the following covariates: age at
diagnosis (continuous), sex, stage of cancer (categorical), number
of comorbidities (0, 1 or X2), treatment (surgery yes/no,
radiotherapy yes/no and chemotherapy yes/no). Missing/unknown
values were included in the multivariable model as missing
indicator. Analysis were performed using Stata statistical software
version 12 (StataCorp, 2011). Statistical tests were two-sided and
considered significant at the Po0.05 level.
Relative survival rates were used to take into account the risk of
dying from causes other than the disease of interest. The excess
mortality reflects the difference between the overall survival of
patients and the survival that would be expected in the absence of
cancer. The excess mortality was calculated as the ratio of the
observed (all-cause) survival proportion to the expected survival
proportion (Dickman and Adami, 2006). National life tables were
used to estimate background mortality (expected survival)
according to sex, year of age and incidence year. Relative excess
risks were estimated using a flexible parametric model, imple-
mented in the Stata command stpm2 (Lambert and Royston,
2009).
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Different parts of the gastrointestinal tract were analysed separately
if there were as at least 10 aspirin users (therefore small bowel,
anal cancer and gastrointestinal tumours NOS were not considered
separately). Histological subtypes (adenocarcinoma and squamous cell
carcinomas) were also analysed separately in groups with at least
10 aspirin users. Statistical interaction for this subgroup was tested
by including an interaction term in the model of aspirin use and
histological subtype and significance was assessed using the Wald test.
A sensitivity analysis was performed by repeating the analysis and
excluding patients with stage IV disease and separately repeating the
analysis and excluding the first year of follow-up from the analysis.
The main analysis and all subgroup analysis were pre-planned.
Pre- and post-diagnosis use of aspirin. For the analysis in patients
that use both aspirin before and after diagnosis, the groups were
selected with the same method as described in the ‘definition of users
and nonusers’ heading. The only difference was that patients who
started aspirin use before diagnosis and continued this after diagnosis
were selected for the group of users of aspirin. Patients using aspirin
only after diagnosis were excluded for this analysis. The statistical
analysis was also equal to the analysis described above, where aspirin
use was analysed as time-varying covariate, and the same factors were
used for the multivariable analysis.
RESULTS
In total 13 715 patients were identified with a cancer of the
gastrointestinal tract diagnosed between January 1998 and
December 2011. The following were excluded from the analysis
(CONSORT diagram Figure 1): 4187 patients who were using
aspirin before diagnosis, 239 patients with follow-up of less than 14
days and three patients below the age of 18 years. Thus, 9286
patients were included in the survival analysis, of which 8278
patients (person years: 4375) did not use aspirin and 1008 (person
years: 2150) used aspirin after diagnosis. In total, 5138 events
(deaths) were recorded. Table 1 shows the characteristics of this
population.
The majority of patients were diagnosed with colon cancer
(43%), rectal cancer (25%) and oesophageal cancer (10%). Median
age at diagnosis was 68 years (interquartile range (IQR) 59–76) in
the aspirin group and 69 (IQR 61–74) in the nonusers group.
Aspirin users were less often female and more frequently diagnosed
with stages I and II disease compared with nonusers. In the
nonusers group, 26% of patients had stage IV disease compared
with 9% in the aspirin users group. Median survival for all patients
was 48 months.
Figure 2 shows survival curves for users of aspirin after
diagnosis vs nonusers. In the group of aspirin users, 65% (95% CI
59–71%) of patients was alive after five years, in contrast to
nonusers, where 45% (95% CI 44–46%) of patients was alive after
five years.
A Cox proportional hazard model was used with use of aspirin
as a time-varying covariate. The proportional hazard assumption
was fulfilled. For all patients with gastrointestinal cancer, aspirin
use was associated with a significant reduction in overall mortality,
hazard ratio (HR) 0.57 (95% confidence interval (CI) 0.48–0.69)
(Table 2). Adjusted for age at diagnosis, sex, stage of cancer,
PHARMO region;
patients with gastrointestinal
cancer;
year of diagnosis 1998–2011
n=13 715
Exclude pre diagnosis
aspirin users
n=4 187
Exclude patients with
follow-up < 14 days
n=239
Patients age < 18 years
n=3
Non-users
n=8 278
Aspirin users
n=1 008
Total database
population
n=9 286
Non-users and post-
diagnosis aspirin users
n=9 528
Figure 1. Flowchart of patients selected for analysis.
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number of comorbidities, treatment (surgery, radiotherapy, and
chemotherapy) the multivariable HR was 0.52 (95% CI 0.44–0.63).
Stratification according to tumour type is shown in Table 2 and
Figure 3. In patients with oesophageal, colon, rectal, and
hepatobiliary tract cancer a significant association was found
between the use of aspirin after diagnosis and overall survival. For
patients with gastric and pancreatic cancer using aspirin, there was
no statistically significant increase in survival. A survival benefit
with aspirin was seen regardless of the stage of cancer at
presentation and after all primary treatment modalities including
chemotherapy, radiotherapy or surgery (Figure 4).
Table 2 additionally shows the relative survival estimates which
are a good estimation of the cancer-specific survival (Sarfati et al,
2010). Equal to the overall survival rates, the observed relative
excess risks were significant in patients with oesophageal cancer,
hepatobiliary cancer, colon and rectal cancer.
Squamous cell cancers accounted for 3% of the total cohort of
which, 81% (n¼ 242) arose from the oesophagus and 18% (n¼ 53)
were anal cancers. Patients with adenocarcinoma of the oesopha-
gus who used aspirin had an adjusted HR 0.24 (95% CI 0.10–0.59)
for overall survival, while those with a squamous cell carcinoma
of the oesophagus had a HR for overall survival of 1.02
(95% CI 0.37–2.83) for aspirin users compared with nonusers.
The test for heterogeneity of the effect of aspirin in patients with
oesophageal squamous cell carcinoma vs patients with oesophageal
adenocarcinoma was significant (P for interaction¼ 0.01).
In 72% of prescriptions, 2435 in total, the dose was reported.
Of all prescribed dosages, 98% were 100mg daily or lower. It was
therefore not possible to analyse a dose–effect relationship, because
only 31 prescriptions were for higher-dose aspirin.
The sensitivity analysis with the exclusion of the first year
follow-up showed a similar effect, with an unadjusted HR of 0.56
Table 1. Characteristics of the cohort
All patients % No aspirin use %
Aspirin post
diagnosis % P-value
Total 9286 100 8278 89 1008 11
Location tumour
Oesophageal cancer 946 10.19 886 10.7 60 5.95
Gastric cancer 750 8.08 700 8.46 50 4.96
Small intestine cancer 97 1.04 88 1.06 9 0.89
Colon cancer 3977 42.83 3434 41.48 543 53.9 o0.001
Rectal cancer 2358 25.39 2069 24.99 289 28.7
Anal cancer 67 0.72 60 0.72 7 0.69
Hepatobiliary cancer 385 4.15 360 4.35 25 2.5
Pancreatic cancer 692 7.45 667 8.06 25 2.47
Cancer of the gastrointestinal tract nos 14 0.15 14 0.17 0 0.0
Sex
Male 5140 55.35 4517 54.6 623 61.8 o0.001
Female 4146 44.65 3761 45.43 385 38.19
Age mean (s.d.). Median (IQR) 67.1 (11) 68 (60–75) 66.7 (12) 68 (59–76) 67.7 (9.9) 69 (61–74)
18–60 Years 2420 26.06 2219 26.8 201 19.9
60–69 Years 2763 29.75 2437 29.4 326 32.3 o0.001
70–79 years 2831 30.49 2464 29.8 367 36.4
80 Years and older 1272 13.7 1158 14 114 11.3
Stage
0 204 2.2 176 2.13 28 2.78
I 1496 16.11 1258 15.2 238 23.56
II 2222 23.93 1900 22.95 322 31.94 o0.001
III 2058 22.16 1788 21.6 270 26.8
IV 2249 24.22 2162 26.12 87 8.63
Unknown 1057 11.4 994 12.01 63 6.25
Surgery
No 2693 29 2603 31.44 90 8.93 o0.001
Yes 6593 71 5675 68.56 918 91.07
Chemotherapy
No 6544 70.47 5798 70.04 746 74.01 0.009
Yes 2742 29.53 2480 29.96 262 25.99
Radiotherapy
No 7042 75.83 6291 76 751 74.5 0.3
Yes 2244 24.17 1987 24 257 25.5
Comorbidities
None 3383 36.43 3056 36.92 327 32.44 0.05
One 2664 28.69 2359 28.5 305 30.26
Two or more 2295 24.71 2027 24.49 268 26.63
Unknown 944 10.17 836 10.1 108 10.69
Morphology
Adenocarcinoma 8343 89.84 7378 89.13 965 95.73 o0.001
Squamous cell carcinoma 298 3.21 280 3.38 18 1.79
Epithelial 140 1.51 135 1.63 5 0.5
Gastrointestinal Stromal tumour 58 0.62 50 0.6 8 0.79
Other (not specified) 447 4.81 435 5.25 12 1.19
Months survival, median (IQR) 48 (15.4–95.4) 24 (7.5–58.6) 89.4 (54.8–132.6)
Abbreviations: IQR¼ interquartile range; nos=not otherwise specified; s.d.=standard deviation.
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(95% C.I. 0.45–0.69) and adjusted HR 0.49 (0.39–0.61). The
sensitivity analysis or stages I–III showed an adjusted HR 0.49
(95% CI 0.39–0.61), consistent with the stratified analysis by stage
in Figure 4.
The analysis in the patients that use aspirin both pre- and post
diagnosis can be found in Table 3. Supplementary Table 1 and
Supplementary Figure 1 show the PRISMA flowchart for this
cohort and the patient characteristics.
DISCUSSION
Aspirin use after diagnosis of a gastrointestinal malignancy is
associated with significantly lower mortality rates and this effect
remains after adjusting for potential cofounders. It was most
marked for tumours arising from the oesophagus, colon, rectum
and hepatobilliary tract. This large cohort study of almost 9300
patients is the first observational cohort study evaluating the
association of aspirin and survival in various gastrointestinal
malignancies. The statistically significant effect on survival
seen in patients with tumours of the oesophagus, colon and
rectum is consistent with data from other published studies
(Chia et al, 2012; Jacobs et al, 2012; Macfarlane et al, 2015; Coyle
et al, 2016; Elwood et al, 2016). The effect in the tumour types
was also present in patients that used aspirin both pre- and post
diagnosis.
In a recent prospective cohort study, Cao et al (2016) found that
the reduced overall reduced cancer risk associated with the use of
aspirin was primarily owing to gastrointestinal tract cancers.
In addition, in a meta-analysis of randomised trials evaluating
aspirin for the prevention of cardiovascular disease, Rothwell et al
(2011) showed a reduced risk of cancer-specific death with aspirin
(HR of 0.79 (95% CI 0.68–0.92)) in all types of cancer. Stratified for
tumour location, the largest benefit was found in patients with
gastrointestinal tumours, with no significant heterogeneity between
different gastrointestinal cancers. Consistent with our study they
also showed that patients with adenocarcinomas were most likely
to benefit from aspirin HR 0.70 (95% CI 0.54–0.91). However,
in contrast, patients in our study only started aspirin after
diagnosis of cancer, which is most relevant when considering
recommendations for subsequent management after a cancer
diagnosis. In our study, 11% of patients started using aspirin after
diagnosis, which is also consistent with previous studies in cancer
patients (McCowan et al, 2013).
A strength of our study is that the data is derived from linked
cancer registry and pharmacy data, eliminating both recall and
information bias. Although we cannot verify that patients actually
ingested the aspirin, the prescriptions registered by the PHARMO
institute are actually handed out to the patients by the pharmacy
and this therefore adds weight to the definition of user. In addition,
immortal time bias and misclassification of exposure in follow-up
is avoided by the use of a Cox proportional hazards model with
time-varying covariate (Suissa and Azoulay, 2012). With this
technique, accurate risk estimates are provided as each individual
prescription is analysed (Stricker and Stijnen, 2010). Moreover, the
exclusion of patients already using aspirin before diagnosis and the
determination of patient characteristics at diagnosis (t¼ 0) mimics
the use of aspirin as adjuvant therapy. In our study, patients are
identified at diagnosis but before they are exposed to the treatment
of interest and differentiated into groups of users and nonusers.
This ‘new-user design’ eliminates important biases associated with
observational studies (Ray, 2003). In addition, it has been suggested
that for measuring the side effects of drugs, which the effect of
aspirin on cancer could theoretically be considered, observational
data could in some cases be considered non-inferior to results from
randomised controlled trials (Vandenbroucke, 2004). Our study
has limitations. First, since exposure to aspirin depends on a
clinician’s decision to prescribe aspirin to a certain patient, it is
prone to confounding by selective prescribing. For instance,
oncologists may withhold aspirin treatment (as secondary preven-
tion for cardiovascular disease) in patients diagnosed with
incurable (stage IV) cancer because of the poor prognosis. Thus
patients with a particularly poor prognosis may end up in the non-
user group. This reverse causation was addressed by the pre-
planned sensitivity analysis excluding the first year of follow-up,
which restricted the study population to patients alive at one year
after diagnosis. By introducing this one year exposure lag, any
undiagnosed recurrence at baseline or early recurrence would have
been likely to become apparent and therefore baseline prognosis
between the two groups is believed to be more similar (Chubak
et al, 2013). Second, proven cardiovascular disease is the main
indication for low-dose aspirin in The Netherlands. This could
imply that patients prescribed aspirin have a worse life
expectancy at baseline because of lifestyle factors and risks
associated with both cardiovascular disease and cancer develop-
ment. Considering the absence of information on cancer-specific
survival and cause of death in our study, hypothetically part of
the overall survival gain we observed could be explained by the
prevention of cardiovascular mortality. However, in a large
meta-analysis of individual participant data, the reduction in
vascular-specific mortality from aspirin was only 9%, HR 0.91
(Baigent et al, 2009). Therefore a reduction in cardiovascular
mortality could only partly explain the reduction in mortality we
observed. Several of the studies evaluating the effect of aspirin
use after a diagnosis of colorectal cancer have shown a significant
reduction in colorectal cancer-specific mortality (Chia et al,
2012; Coyle et al, 2016). Third, over the counter aspirin use was
not included. However, prescription data can give valid
estimations of association even though available over the counter
(Yood et al, 2007). No data were available to adjust for lifestyle
factors, health-related behaviour and mutational status. Lastly,
Table 1 shows that the groups aspirin users and nonusers are
different with respect to baseline characteristics. This is to a large
extent the result of the size of the cohort. After adjustment for
these factors the association between aspirin use and survival
remained significant. Nevertheless, the confounding by indica-
tion as described remains, and therefore randomised controlled
trials remain inevitable before aspirin can be used as regular anti-
cancer treatment.
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Figure 2. Survival comparison for aspirin users vs nonusers with
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The mechanism responsible for the effect of aspirin on cancer
remains unknown. Aspirin (acetylsalicylic acid) reduces prosta-
noid generation by irreversible inhibition of platelet COX-1
(cyclooxygenase-1) and COX-2 isozymes. Activated platelets
release several growth factors which impact on tumour progres-
sion and metastasis (Bruno et al, 2012). Maximum platelet
inactivation by COX-1 is thought to be obtained by low-dose
aspirin (75–100mg daily) and over 95% of platelet activity is
inhibited for up to 24 h (Patrignani et al, 2014). A number of
potential biomarkers have been identified as predictors of
response to aspirin in terms of cancer outcomes. Chan et al
(2009) reported that the effect of high-dose (325mg) aspirin after
a colorectal cancer diagnosis was predominantly in patients with
COX-2 (also called PTGS2) overexpression. However, to achieve
constant inhibition of COX in tissues, the administered daily
dose of aspirin would have to be higher than 2000mg (Thun
et al, 2012). In some studies mutations in phosphatidylinositol 3-
kinase (PIK3CA) have been associated with aspirin response;
however, in a previous study we did not find this association but
showed that the effect of aspirin was associated with tumours
that expressed human leukocyte antigen (HLA) class1 molecules
(Reimers et al, 2014; Paleari et al, 2015).
Our observation that aspirin use is similarly associated
with good prognosis in various tumour types with clearly
different biology makes a nonspecific mode of action plausible.
It is possible that aspirin executes its effect by inhibiting
platelet aggregation around circulating epithelial tumour cells,
irrespective of organ site which then facilitates immune
clearance. The coming years will hopefully provide answers.
Several randomised clinical trials have commenced in the past
years (NCT02647099 (Langley and Rothwell, 2014),
NCT02467582, NCT02301286, NCT00565708). Many of these
trials are united in the ‘Aspirin Trialist Collaborative Group’ and
will pool results regarding clinical outcome and expression
of biomarkers.
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Oesophageal cancer
Gastric cancer
Pancreatic cancer
Hepatobilliary tract cancer
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Figure 3. Overall survival analysis for aspirin users vs nonusers
stratified according to tumour type.
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Figure 4. Forest plot of adjusted overall survival analysis in patients
with gastrointestinal malignancies grouped according to aspirin users
vs nonusers and stratified for stage and treatment.
Table 3. Time-dependent survival analysis (overall survival) stratified according to tumour type with prediagnosis aspirin users
Overall survival
No. at risk No. events
Crude hazard
ratio
95% CI P-value Adjusted hazard
ratioa
95% CI P-value
Aspirin users vs nonusers (n¼12109)
Nonusers 8366 4913 1 (Reference) 1 (Reference)
Pre and post-diagnosis aspirin usersb 2736 1647 0.69 0.64–0.75 o0.001 0.61 0.57–0.66 o0.001
Aspirin users vs nonusers per tumour type
Oesophageal cancer (n¼1180)
Nonusers 894 741 1 (Reference) 1 (Reference)
Aspirin Usersb 286 229 0.64 0.52–0.79 o0.001 0.61 0.49–0.76 o0.001
Gastric cancer (n¼933)
Nonusers 714 574 1 (Reference) 1 (Reference)
Aspirin Usersb 219 184 0.90 0.72–1.13 0.37 0.85 0.67–1.07 0.17
Pancreatic cancer (n¼876)
Nonusers 681 648 1 (Reference) 1 (Reference)
Aspirin Usersb 195 183 0.68 0.54–0.84 o0.001 0.67 0.53–0.84 0.001
Hepatobiliary cancer (n¼477)
Nonusers 364 317 1 (Reference) 1 (Reference)
Aspirin Usersb 113 101 0.81 0.61–1.08 0.16 0.69 0.51–0.93 0.02
Colon cancer (n¼4730)
Nonusers 3469 1642 1 (Reference) 1 (Reference)
Aspirin Usersb 1261 612 0.67 0.59–0.76 o0.001 0.55 0.48–0.63 o0.001
Rectal cancer (n¼2687)
Nonusers 2080 910 1 (Reference) 1 (Reference)
Aspirin Usersb 607 306 0.78 0.65–0.94 0.008 0.63 0.52–0.75 o0.001
Abbreviation: CI¼ confidence interval.
aAdjusted for stage, sex, age at diagnosis, surgery, radiotherapy, chemotherapy and comorbidities.
bOnly patients using aspirin both pre- and post diagnosis were analysed.
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CONCLUSION
Aspirin use after diagnosis of gastrointestinal malignancies is
associated with improved overall survival. This observation makes
a nonspecific mode of action for aspirin on cancer plausible. These
results offer direction towards future studies, both in terms of new
randomised controlled trials as well as further studies to identify
biomarkers that predict response to aspirin.
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